X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5621) 5621
Book Chapter (19) 19
Magazine Article (18) 18
Newspaper Article (12) 12
Dissertation (9) 9
Conference Proceeding (4) 4
Publication (2) 2
Trade Publication Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
immunotherapy (2638) 2638
pd-l1 protein (2619) 2619
humans (2436) 2436
pd-l1 (2408) 2408
oncology (2383) 2383
cancer (2167) 2167
tumors (1884) 1884
apoptosis (1675) 1675
lymphocytes (1467) 1467
pd-1 protein (1436) 1436
immune checkpoint (1306) 1306
lymphocytes t (1272) 1272
female (1187) 1187
immunology (1130) 1130
patients (1057) 1057
chemotherapy (1040) 1040
pd-1 (1032) 1032
expression (1028) 1028
ligands (1024) 1024
lung cancer (974) 974
metastasis (950) 950
male (907) 907
immunohistochemistry (886) 886
melanoma (871) 871
animals (854) 854
cancer therapies (847) 847
metastases (830) 830
nivolumab (823) 823
prognosis (814) 814
b7-h1 antigen - metabolism (794) 794
pd-l1 expression (787) 787
middle aged (785) 785
cell death (783) 783
survival (730) 730
gene expression (723) 723
medical prognosis (722) 722
pembrolizumab (712) 712
biomarkers (707) 707
aged (704) 704
immune system (686) 686
blockade (675) 675
antigens (634) 634
clinical trials (623) 623
t cells (616) 616
care and treatment (615) 615
mutation (615) 615
adult (598) 598
proteins (597) 597
cytotoxicity (588) 588
cd8 antigen (566) 566
mice (564) 564
t-cells (545) 545
immune response (543) 543
research (540) 540
pathology (532) 532
tumor-infiltrating lymphocytes (522) 522
tumor cells (501) 501
therapy (498) 498
analysis (495) 495
antibodies (494) 494
safety (463) 463
cell biology (456) 456
non-small cell lung carcinoma (455) 455
b7-h1 antigen - genetics (451) 451
activation (449) 449
dendritic cells (449) 449
open-label (443) 443
b7-h1 antigen - immunology (431) 431
medical research (431) 431
health aspects (429) 429
breast cancer (426) 426
carcinoma (410) 410
cell line, tumor (404) 404
cytokines (391) 391
inflammation (384) 384
anti-pd-l1 antibody (382) 382
multidisciplinary sciences (380) 380
review (378) 378
b7-h1 antigen - antagonists & inhibitors (374) 374
medicine, research & experimental (374) 374
studies (368) 368
kinases (363) 363
aged, 80 and over (357) 357
flow cytometry (356) 356
medicine & public health (351) 351
genetic aspects (350) 350
ipilimumab (347) 347
programmed cell death 1 receptor - antagonists & inhibitors (342) 342
b7-h1 (340) 340
medicine (333) 333
ctla-4 protein (329) 329
docetaxel (329) 329
signal transduction (328) 328
immunoglobulins (325) 325
immunotherapy - methods (325) 325
tumor microenvironment (317) 317
immunity (312) 312
macrophages (311) 311
monoclonal antibodies (311) 311
programmed cell death 1 receptor - immunology (311) 311
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5600) 5600
Chinese (37) 37
French (24) 24
German (22) 22
Japanese (15) 15
Korean (6) 6
Russian (3) 3
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature (London), ISSN 1476-4687, 2017, Volume 553, Issue 7686, pp. 91 - 95
Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1... 
CELLS | THERAPY | IMMUNOTHERAPY | STABILIZATION | MULTIDISCIPLINARY SCIENCES | PROSTATE-CANCER | RETINOBLASTOMA-PROTEIN | SPOP | DEPENDENT KINASES | BREAST | REQUIREMENT | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Immunologic Surveillance | Phosphorylation | Humans | Male | Prostatic Neoplasms - immunology | Proteolysis | Cullin Proteins - metabolism | Female | Protein Stability | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Repressor Proteins - metabolism | Tumor Escape - immunology | Cdh1 Proteins - metabolism | Lymphocytes, Tumor-Infiltrating - cytology | Cell Line | Repressor Proteins - chemistry | Programmed Cell Death 1 Receptor - metabolism | Nuclear Proteins - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Nuclear Proteins - chemistry | 14-3-3 Proteins - metabolism | B7-H1 Antigen - metabolism | Animals | Cell Cycle | Neoplasms - immunology | B7-H1 Antigen - biosynthesis | Mice | Proteasome Endopeptidase Complex - metabolism | Cyclin D - metabolism | Lymphocytes, Tumor-Infiltrating - immunology | Animal models | PD-1 protein | Kinases | Cyclin-dependent kinase 4 | Cullin | Degradation | Proteins | Ubiquitination | Cell growth | Lymphocytes | Immunotherapy | Cell cycle | Cyclin D | Ubiquitin-protein ligase | Cyclin-dependent kinases | L1 protein | Immunosurveillance | Anaphase-promoting complex | Patients | Molecular modelling | Immune checkpoint | Cell death | Medical prognosis | PD-L1 protein | Ligands | Mutation | Anaphase | Prostate cancer | Prostate | Tumors | Apoptosis | Cancer
Journal Article
Nature (London), ISSN 1476-4687, 2017, Volume 547, Issue 7664, pp. 413 - 418
Immunotherapy with PD-1 checkpoint blockade is effective in only a minority of patients with cancer, suggesting that additional treatment strategies are... 
CELLS | GENE | MULTIDISCIPLINARY SCIENCES | CD94/NKG2A | BLOCKADE | EXPRESSION | PD-1 | HLA-E | Tumor Escape - drug effects | Immunotherapy - methods | Loss of Function Mutation | Tumor Escape - genetics | Genomics | Humans | NF-kappa B - metabolism | Interferons - immunology | Melanoma, Experimental - immunology | T-Lymphocytes - drug effects | Tumor Escape - immunology | Melanoma, Experimental - therapy | Melanoma, Experimental - pathology | Antigen Presentation - genetics | Protein Tyrosine Phosphatase, Non-Receptor Type 2 - deficiency | Protein Tyrosine Phosphatase, Non-Receptor Type 2 - genetics | Antigen Presentation - immunology | Unfolded Protein Response | CRISPR-Cas Systems - genetics | Gene Editing | Xenograft Model Antitumor Assays | Protein Tyrosine Phosphatase, Non-Receptor Type 2 - metabolism | Animals | Melanoma, Experimental - genetics | T-Lymphocytes - immunology | Mice | Care and treatment | Analysis | Immunotherapy | Diagnosis | Genetic screening | Methods | Cancer | Animal models | PD-1 protein | Genes | Genomes | Synergism | Proteins | Signal transduction | Clonal deletion | Lymphocytes | Protein folding | Tyrosine | Antigen presentation | NF-κB protein | CRISPR | Melanoma | Medical screening | Patients | Screening | Signaling | Immune checkpoint | PD-L1 protein | Interferon | Genetic testing | Tumors | Protein-tyrosine-phosphatase | PTPN2 protein
Journal Article
Clinical cancer research, ISSN 1557-3265, 2017, Volume 23, Issue 14, pp. 3585 - 3591
Journal Article
Nature (London), ISSN 1476-4687, 2017, Volume 549, Issue 7670, pp. 106 - 110
Journal Article
ACS Nano, ISSN 1936-0851, 10/2017, Volume 11, Issue 10, pp. 10135 - 10146
Programmed cell death protein-1 (PD-1) is a prominent immune checkpoint receptor interacting with its ligand, programmed cell death protein ligand-1 (PD-L1, B7-H1... 
mTOR pathway | PD-L1 | siRNA delivery | polyelectrolyte carrier | B16F10 melanoma | immune checkpoint blockade | GENE DELIVERY | PD-L1 EXPRESSION | IFN-GAMMA | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | OVARIAN-CANCER | CHEMISTRY, MULTIDISCIPLINARY | LUNG-CANCER | SIGNALING PATHWAY | IN-VIVO | ANTITUMOR IMMUNITY | TUMOR-GROWTH | PROGRESSION
Journal Article
Immunity (Cambridge, Mass.), ISSN 1074-7613, 2017, Volume 47, Issue 6, pp. 1083 - 1099.e6
The immunosuppressive protein PD-L1 is upregulated in many cancers and contributes to evasion of the host immune system... 
PD-L1 | TTP | KRAS | RAS | tristetraprolin | immunotherapy | CELL LUNG-CANCER | ACTIVATED PROTEIN-KINASE | EPITHELIAL-CELLS | TRISTETRAPROLIN | MELANOMA-CELLS | TNF-ALPHA | IMMUNOLOGY | EXPRESSION | CHECKPOINT BLOCKADE | Proto-Oncogene Proteins p21(ras) - immunology | Neoplasm Transplantation | RNA, Messenger - immunology | Tumor Escape | Proto-Oncogene Proteins p21(ras) - genetics | Tristetraprolin - immunology | Colorectal Neoplasms - genetics | Humans | Gene Expression Regulation, Neoplastic | Intracellular Signaling Peptides and Proteins - immunology | Lung Neoplasms - pathology | Male | Female | Intracellular Signaling Peptides and Proteins - genetics | Lung Neoplasms - genetics | Signal Transduction | MAP Kinase Kinase Kinases - genetics | Mice, Inbred C57BL | RNA, Messenger - genetics | Protein-Serine-Threonine Kinases - genetics | Epithelial Cells - pathology | RNA Cleavage | RNA Stability | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | MAP Kinase Kinase Kinases - immunology | Lung Neoplasms - immunology | Animals | Colorectal Neoplasms - immunology | Tristetraprolin - genetics | Epithelial Cells - immunology | Cell Line, Tumor | Protein Binding | Protein-Serine-Threonine Kinases - immunology | Mice | Mice, Inbred BALB C | Colorectal Neoplasms - pathology | Messenger RNA | Gastrointestinal diseases | Immunotherapy | Colorectal cancer | Cellular signal transduction | Cancer | Protein binding | Transcription factors | Phosphorylation | Lung cancer | Genomes | Kinases | Proteins | Signal transduction | Restoration | DNA methylation | Tumor necrosis factor-TNF | Oncogenes | Immune system | Cytokines | Ras protein | Ribonucleic acid--RNA | Gene expression | Patients | Signaling | Immunosuppression | 3' Untranslated regions | Ligands | Protein expression | Mutation | Tumors
Journal Article
Molecular cancer research, ISSN 1557-3125, 2017, Volume 15, Issue 6, pp. 753 - 764
Journal Article
Oncogene, ISSN 1476-5594, 2018, Volume 37, Issue 29, pp. 3998 - 4012
...) is the only viral protein to be consistently expressed. EBNA1 is required for viral genome propagation and segregation during latency... 
SURVIVAL | PROTEIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | TRANSCRIPTION | P53 | CELL BIOLOGY | IN-VITRO | ONCOLOGY | BURKITTS-LYMPHOMA | GENETICS & HEREDITY | EXPRESSION | IMMORTALIZATION | TUMORIGENESIS | TRANSGENIC MICE | Gene Expression Regulation, Viral - physiology | Interleukin-2 - metabolism | Cell Line | Epstein-Barr Virus Infections - virology | Humans | Mice, Inbred C57BL | Tumor Suppressor Protein p53 - metabolism | Mice, Transgenic | E2F1 Transcription Factor - metabolism | Proto-Oncogene Proteins c-myc - metabolism | Lymphoma - metabolism | B7-H1 Antigen - metabolism | Animals | Cell Death - physiology | Up-Regulation - physiology | CD8-Positive T-Lymphocytes - metabolism | Herpesvirus 4, Human - metabolism | Epstein-Barr Virus Infections - metabolism | Epstein-Barr Virus Nuclear Antigens - metabolism | Proto-Oncogene Proteins c-mdm2 - metabolism | Lymphoma - virology | Care and treatment | Development and progression | Epstein-Barr virus | Genetic aspects | Lymphomas | Health aspects | Viral antigens | Phosphorylation | CD8 antigen | p53 Protein | c-Myc protein | XIAP protein | Genomes | Lymphocytes T | Myc protein | Proteins | Interleukin 2 | Rodents | Tumorigenesis | Stat1 protein | c-Fos protein | Antigens | MDM2 protein | Cell survival | Transgenic mice | Gene expression | Lymphoma | Latency | Cell death | PD-L1 protein | Isoforms | Tumors | EBV | Mdm2 | EBNA1 | c-Myc | lymphoma
Journal Article
Cancer, ISSN 0008-543X, 2017, Volume 123, Issue S11, pp. 2118 - 2129
...‐activated protein kinase (MAPK) and phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT) signaling pathways. Selective inhibitors targeting key effectors... 
targeted therapy | phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT) pathway | BRAF inhibitors | mitogen‐activated protein kinase kinase (MEK) inhibitors | immunotherapy | melanoma | mitogen‐activated protein kinase (MAPK) pathway | phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway | mitogen-activated protein kinase kinase (MEK) inhibitors | mitogen-activated protein kinase (MAPK) pathway | MUTANT MELANOMA | PD-L1 EXPRESSION | ACQUIRED-RESISTANCE | OPEN-LABEL | MEK INHIBITORS | METASTATIC MELANOMA | PHASE-II TRIAL | ONCOLOGY | CUTANEOUS MELANOMA | BRAF INHIBITOR RESISTANCE | RAF INHIBITORS | Niacinamide - analogs & derivatives | Immunotherapy - methods | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - genetics | MAP Kinase Kinase 1 - genetics | Melanoma - genetics | Benzimidazoles - therapeutic use | MAP Kinase Kinase 1 - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Signal Transduction | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Phosphatidylinositol 3-Kinases - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Melanoma - drug therapy | Skin Neoplasms - genetics | Indoles - therapeutic use | CTLA-4 Antigen - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Therapy | Melanoma | MAP kinase | AKT protein | Drug resistance | Kinases | Cancer therapies | Patients | 1-Phosphatidylinositol 3-kinase | Metastases | Signal transduction | Inhibitors | Pathways | New combinations | Effectors | Mutation | Cancer
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 11, p. e0166626
Ectopic programmed cell death ligand 1 (PD-L1) expression in non-small cell lung cancers (NSCLCs) is related to immune evasion by cancer, and it is a molecular... 
TARGETED THERAPY | MIGRATION | CELLS | METASTASIS | MELANOMA | PATHWAY | IFN-GAMMA | MULTIDISCIPLINARY SCIENCES | B7-H1 | INFECTION | IMMUNE EVASION | Lung Neoplasms - drug therapy | RNA, Small Interfering - genetics | Adenocarcinoma - pathology | Adenocarcinoma of Lung | Proto-Oncogene Proteins p21(ras) - genetics | Transcription Factor AP-1 - genetics | Humans | ErbB Receptors - genetics | Lung Neoplasms - pathology | Cell Movement - genetics | Nitriles - administration & dosage | Phorbols - administration & dosage | Adenocarcinoma - genetics | Gene Expression Regulation, Neoplastic - drug effects | STAT3 Transcription Factor - genetics | Lung Neoplasms - genetics | Cell Adhesion - genetics | Mitogen-Activated Protein Kinases - biosynthesis | Adenocarcinoma - drug therapy | B7-H1 Antigen - genetics | STAT3 Transcription Factor - biosynthesis | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Signaling System - drug effects | Butadienes - administration & dosage | Transcription Initiation Site | Mitogen-Activated Protein Kinases - genetics | Mutation | Genes | Luciferase | B cells | Genetic transcription | Comparative analysis | Lung cancer, Non-small cell | Mitogens | Protein kinases | Apoptosis | Adenocarcinoma | Cluster analysis | Biotechnology | Chromatin | Transcription factors | Immunoprecipitation | Transcription | Downstream effects | Lung cancer | Science | Oncology | Metastasis | Kinases | K-Ras protein | Lymphocytes | L1 gene | Antigens | Epidermal growth factor receptors | Activator protein 1 | Stat3 protein | Extracellular signal-regulated kinase | Non-small cell lung carcinoma | MAP kinase | Tumor cell lines | Gene expression | 1-Phosphatidylinositol 3-kinase | Signaling | Inhibitors | Immune checkpoint | Lungs | Protein kinase | Cell death | PD-L1 protein | Dimethyl sulfoxide | Ligands | Lymphomas | Acetic acid | Phorbol 12-myristate 13-acetate
Journal Article